.png){kind=small}
Our Company
Humanwell Pharmaceutical US, Inc. is a Missouri-incorporated pharmaceutical research and development company that focuses on the development of novel therapies to address unmet medical needs. Humanwell US is an independent subsidiary company of Yichang Humanwell Pharmaceutical Co. LTD.
Our Parent Company
Yichang Humanwell Pharmaceutical Co. LTD, is a global market leader in anesthetic and pain medications. More than 4,000 employees work together to deliver products to over 20 countries, helping to make the world a healthier and happier place.
Humanwell Locations Across the Globe
Our Values
Integrity
We operate with the highest integrity and ethical standard.
Innovation
We strive to be at the forefront of our field, bringing innovative treatment to patients and healthcare providers.
Collaboration
We collaborate with our colleagues and external partners to develop medicines to address unmet medical needs.
Passion
We are passionate and committed to what we do every day.
Making a Difference
We believe that we can make a difference in each patient's life and improve global human well-being.
Our Company History
September 2015
Humanwell US was founded.
December 2016
DEA registrations obtained.
May 2018
Branded Products Department established.
Q4 2020
First ANDA filing & first NCE compound enters GLP.
Q3 2022
First 505(b)(2) project enters GLP.
Q3 2023
Second ANDA approval.
August 2016
Grand opening of laboratory.
May 2017
Tech transfer of developed oral products.
September 2019
Lab expansion for NCE & complex injectables.
Q2 2022
First ANDA approval.
Q1 2023
First NDA project approved by FDA enters Phase 1 clinical trial.